Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofogliflozin vs Metformin in Diabetic Kidney Disease
NCT05469659Phase 2Recruiting
- Sponsor
- Shinshu University
- Start
- Sep 2021
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tofogliflozin in diabetic kidney disease (DKD) (2 arms), sponsored by Shinshu University. Primary endpoint: Urine Albumin-to-Creatinine Ratio at 52 weeks. Started Sep 2021; status: recruiting.
02
Drugs
tofogliflozin
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT05469659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469659.